NLTX
Income statement / Annual
Last year (2024), Neoleukin Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Neoleukin Therapeutics, Inc.'s net income was -$75.14 M.
See Neoleukin Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2024 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00 |
$0.00 |
$6.00 K |
$451.00 K |
$0.00 |
$25.00 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$6.00 K
|
$451.00 K
|
$0.00
|
$25.00 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
1
|
1
|
0
|
1
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$60.92 M
|
$41.13 M
|
$39.16 M
|
$24.34 M
|
$4.42 M
|
$41.79 M
|
$36.27 M
|
$28.38 M
|
$15.80 M
|
$18.08 M
|
| General & Administrative Expenses |
$22.61 M
|
$17.97 M
|
$21.54 M
|
$17.21 M
|
$18.83 M
|
$15.84 M
|
$14.85 M
|
$9.26 M
|
$5.54 M
|
$4.30 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$22.61 M
|
$17.97 M
|
$21.54 M
|
$17.21 M
|
$18.83 M
|
$15.84 M
|
$14.85 M
|
$9.26 M
|
$5.54 M
|
$4.30 M
|
| Other Expenses |
$0.00
|
-$42.00 K
|
$6.00 K
|
-$44.00 K
|
-$8.00 K
|
-$445.00 K
|
-$39.00 K
|
-$43.00 K
|
$0.00
|
$0.00
|
| Operating Expenses |
$83.53 M
|
$59.10 M
|
$60.70 M
|
$41.55 M
|
$23.24 M
|
$57.62 M
|
$51.12 M
|
$37.65 M
|
$21.34 M
|
$22.38 M
|
| Cost And Expenses |
$0.00
|
$59.10 M
|
$60.70 M
|
$41.55 M
|
$23.24 M
|
$57.62 M
|
$51.12 M
|
$37.65 M
|
$21.34 M
|
$22.38 M
|
| Interest Income |
$8.47 M
|
$1.58 M
|
$19.00 K
|
$490.00 K
|
$1.54 M
|
$1.56 M
|
$998.00 K
|
$619.00 K
|
$0.00
|
$0.00
|
| Interest Expense |
-$12.00 K
|
$1.58 M
|
$0.00
|
$0.00
|
$1.00 K
|
$4.00 K
|
$4.00 K
|
$1.00 K
|
$99.00 K
|
$461.59 K
|
| Depreciation & Amortization |
$0.00
|
$2.61 M
|
$2.28 M
|
-$13.84 M
|
$49.59 M
|
$1.04 M
|
$940.00 K
|
$644.00 K
|
-$421.00 K
|
$135.95 K
|
| EBITDA |
-$82.61 M |
-$53.36 M |
-$60.70 M |
-$47.56 M |
-$21.37 M |
-$31.51 M |
-$50.16 M |
-$37.07 M |
-$21.71 M |
-$24.38 M |
| EBITDA Ratio |
0
|
0
|
-10116.33
|
-105.46
|
0
|
-1.26
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
-10116.33
|
-74.78
|
0
|
-1.3
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$7.46 M
|
$1.54 M
|
$6.00 K
|
$7.83 M
|
$1.52 M
|
$1.04 M
|
$936.00 K
|
$643.00 K
|
-$520.00 K
|
$487.60 K
|
| Income Before Tax |
-$75.14 M
|
-$57.56 M
|
-$60.69 M
|
-$33.28 M
|
-$69.44 M
|
-$31.59 M
|
-$50.18 M
|
-$37.00 M
|
-$21.86 M
|
-$24.03 M
|
| Income Before Tax Ratio |
0
|
0
|
-10115.33
|
-73.78
|
0
|
-1.26
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
-$1.54 M
|
-$2.28 M
|
-$8.32 M
|
-$7.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$222.00
|
| Net Income |
-$75.14 M
|
-$57.56 M
|
-$60.69 M
|
-$33.28 M
|
-$69.44 M
|
-$31.59 M
|
-$50.18 M
|
-$37.00 M
|
-$21.86 M
|
-$23.82 M
|
| Net Income Ratio |
0
|
0
|
-10115.33
|
-73.78
|
0
|
-1.26
|
0
|
0
|
0
|
0
|
| EPS |
-3.96 |
-5.07 |
-5.31 |
-3.2 |
-12.85 |
-6.71 |
-10.7 |
-9.79 |
-8.65 |
-13.74 |
| EPS Diluted |
-3.96 |
-5.07 |
-5.5 |
-3.2 |
-12.85 |
-1.34 |
-10.7 |
-9.79 |
-8.65 |
-13.74 |
| Weighted Average Shares Out |
$18.98 M
|
$11.04 M
|
$11.01 M
|
$10.37 M
|
$5.41 M
|
$4.71 M
|
$4.69 M
|
$3.78 M
|
$2.53 M
|
$1.73 M
|
| Weighted Average Shares Out Diluted |
$18.98 M
|
$11.04 M
|
$11.01 M
|
$10.37 M
|
$5.41 M
|
$23.52 M
|
$4.69 M
|
$3.78 M
|
$2.53 M
|
$1.73 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
